[go: up one dir, main page]

MX2022000525A - Vacunas contra la ehrlichia y composiciones inmunogenicas. - Google Patents

Vacunas contra la ehrlichia y composiciones inmunogenicas.

Info

Publication number
MX2022000525A
MX2022000525A MX2022000525A MX2022000525A MX2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A
Authority
MX
Mexico
Prior art keywords
immunogenic compositions
vaccines against
ehrlichia
against ehrlichia
adjuvant
Prior art date
Application number
MX2022000525A
Other languages
English (en)
Inventor
Paul J Dominowski
Suman Mahan
Jere W Mcbride
Jason J Millership
Duncan M Mwangi
Sharath Rai
Sharon M Wappel
Original Assignee
Res Found Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Found Dev filed Critical Res Found Dev
Publication of MX2022000525A publication Critical patent/MX2022000525A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1246—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Rickettsiales (O)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se proporcionan composiciones inmunogénicas que se pueden utilizar, en algunos aspectos, para inducir una respuesta inmunitaria contra una Ehrlichia como Ehrlichia canis. En algunas modalidades, la composición inmunogénica comprende una bacterina de E. canis y/o un adyuvante, como por ejemplo una emulsión o un adyuvante liposomal. Asimismo se proporcionan métodos relacionados, como para el diagnóstico o la vacunación contra la ehrlichiosis.
MX2022000525A 2019-07-12 2020-07-13 Vacunas contra la ehrlichia y composiciones inmunogenicas. MX2022000525A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962873843P 2019-07-12 2019-07-12
US201962879762P 2019-07-29 2019-07-29
US202063049476P 2020-07-08 2020-07-08
PCT/US2020/041779 WO2021011456A1 (en) 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions

Publications (1)

Publication Number Publication Date
MX2022000525A true MX2022000525A (es) 2022-04-20

Family

ID=71948757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000525A MX2022000525A (es) 2019-07-12 2020-07-13 Vacunas contra la ehrlichia y composiciones inmunogenicas.

Country Status (11)

Country Link
US (1) US20220356231A1 (es)
EP (1) EP3996741A1 (es)
JP (1) JP2022540197A (es)
CN (1) CN114514238A (es)
AU (1) AU2020314625A1 (es)
BR (1) BR112022000347A2 (es)
CA (1) CA3146842A1 (es)
CL (1) CL2022000086A1 (es)
MX (1) MX2022000525A (es)
PH (1) PH12022550081A1 (es)
WO (1) WO2021011456A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025118050A1 (pt) * 2023-12-04 2025-06-12 Laboratório Bio-Vet Ltda Antígeno vacinal quimérico com ação tríplice contra erliquiose, anaplasmose e babesiose canina, vetor de expressão, célula recombinante, composição vacinal, kit de diagnóstico, método de tratamento e uso de proteína quimérica

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
JP4494974B2 (ja) * 2002-11-04 2010-06-30 リサーチ ディベロップメント ファウンデーション イヌおよびヒトエールリヒア症の免疫診断のためのｐ１５３およびｐ１５６抗原ならびにその使用
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
CA2563502A1 (en) * 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
US7842474B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
WO2006107924A2 (en) * 2005-04-04 2006-10-12 Idexx Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
WO2006138509A2 (en) * 2005-06-16 2006-12-28 Research Development Foundation Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis
WO2008000070A1 (en) * 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
CA2662246C (en) * 2006-08-31 2016-07-05 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
EP3725328A3 (en) * 2008-06-27 2020-12-23 Zoetis Services LLC Novel adjuvant compositions
WO2010126993A1 (en) * 2009-04-28 2010-11-04 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
JP2011251963A (ja) * 2010-05-28 2011-12-15 Coley Pharmaceutical Group Inc 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
WO2013181086A1 (en) * 2012-05-31 2013-12-05 Zoetis Llc Vaccination with canine respiratory coronavirus for protection against b. bronchiseptica infections
CN105764525A (zh) * 2013-09-19 2016-07-13 硕腾服务有限责任公司 油基佐剂
US11046734B2 (en) * 2018-07-27 2021-06-29 Research Development Foundation Chimeric immunogenic polypeptides

Also Published As

Publication number Publication date
WO2021011456A1 (en) 2021-01-21
CN114514238A (zh) 2022-05-17
CA3146842A1 (en) 2021-01-21
CL2022000086A1 (es) 2022-09-30
AU2020314625A1 (en) 2022-02-03
BR112022000347A2 (pt) 2022-04-12
JP2022540197A (ja) 2022-09-14
US20220356231A1 (en) 2022-11-10
PH12022550081A1 (en) 2023-04-12
EP3996741A1 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
MX2021000193A (es) Selección de epítopos de vacunas personalizadas contra el cáncer.
MX2023000211A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
CR20140436A (es) Vacuna de combinación contra mycoplasma hyopneumoniae
CL2015001111A1 (es) Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna.
CO7160025A2 (es) Vacuna de combinación contra pcv/mycoplasma hyopneumoniae
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
PE20151588A1 (es) Vacuna contra el virus del dengue
MX2020004367A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CL2016002402A1 (es) Composiciones inmunológicas que contiene histophilus somni atenuado
BR112019003992A2 (pt) vacina contra neisseria meningitidis
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
MX2023012390A (es) Vacunacion con particulas de replicon y adyuvante oleoso.
MX2016001695A (es) Composiciones inmunogenas de combinacion.
MX2016016080A (es) Vacunas guiadas por anticuerpos y metodos de uso para generar respuestas imunitarias maduras rapidas.
AR089995A1 (es) Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
MX2022000525A (es) Vacunas contra la ehrlichia y composiciones inmunogenicas.
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
MX2017006744A (es) Composiciones adyuvantes y metodos relacionados.